

Q1-2020 Pharmaceutical Services Update

Market Update

Merger and acquisition activity in the pharmaceutical CDMO and CRO sectors was primarily concentrated in the European region during the first quarter of 2020. While North America remains the most active region for consolidation due to its FDA/NDA access and growth opportunity, Europe possesses unmatched research talent, infrastructure, and qualified human capital. This dynamic has allowed Europe to become a leader in innovative cell and gene therapy development, which has attracted unprecedented funding in recent years.

Select Transactions:

| Month | Acquirer | Target | Target Focus | Deal Description |
|---------|-----------------------|--------------------|--------------|---|
| March | Frontage Laboratories | Biotranix | CRO | Biotranix, a U.S. based pharmacokinetic and metabolism research facility has been acquired by Frontage Laboratories. The acquisition fills a gap in Frontage's capabilities in transporter assaying and broader pharmacokinetic research. |
| March | Nuvisan Pharma | Inamed GMBH | CRO | Nuvisan Pharma has acquired Inamed GMBH, a CRO focused on cystic fibrosis. As one of the few providers of research services utilizing orally inhaled products flow-studies in the world, Inamed has been able to consistently recruit patients for rare disease studies. |
| March | Exothera | Softimat | CDMO | Exothera has acquired a manufacturing facility in Belgium from Softimat in its effort to expand into cell and gene development. The company funded the acquisition with the help of its private equity sponsor, KKR which invested in Exothera in 2019. |
| March | Catalent | MaSTherCell Global | CDMO | Catalent has acquired MaSTherCell Global from Orgenesis, a portfolio company of Great Point Partners. The acquisition complements Catalent's' recent investments in gene and cell therapy development, which have received unprecedented levels of funding in the past few years. |
| Janaury | GHO Capital | Ardena | CDMO | GHO Capital has completed a majority recapitalization of Ardena, a full service CDMO to small and mid-size biopharmaceutical clients. The Company employs 300+ people across its offices in Europe, Asia, and North America. |

Provident Industry Coverage Team